Company / Cash & Equivalents
AVADEL PHARMACEUTICALS PLC Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$51.4M
FY2024
5-year range
$31.2M / $74.0M
FY2020-FY2024
Trend
+64.8%
vs FY2023
Sector context
#180 of 207
Health Care
What the data says
AVADEL PHARMACEUTICALS PLC's cash & equivalents of $51M is lower than 87% of companies in the Health Care sector (FY2024). Cash & Equivalents has fluctuated over the past 10 years, ranging from $9M in FY2018 to $74M in FY2022.
Based on SEC 10-K filings.
$51M in FY2024 with a 5-year CAGR of +39.4%.
Declined from $74M to $51M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +0.4%
- 5-Year CAGR
- +39.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 207This company $51.4M Sector average $669.5M
▼
-92.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +39.4%, indicating consistent growth.
- In FY2024, cash & equivalents increased 64.8% year-over-year.
- Ranks #180 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $51.4M | +64.8% |
| FY2023 | $31.2M | -57.9% |
| FY2022 | $74.0M | +45.9% |
| FY2021 | $50.7M | -29.3% |
| FY2020 | $71.7M | +633.8% |
| FY2019 | $9.8M | +4.8% |
| FY2018 | $9.3M | -43.7% |
| FY2017 | $16.6M | -57.8% |
| FY2016 | $39.2M | -39.7% |
| FY2015 | $65.1M | +63.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026